Revealing the Mechanism of Action of a First-in-Class Covalent Inhibitor of KRASG12C (ON) and Other Functional Properties of Oncogenic KRAS by 31P NMR

Bridgebio Oncology Therapeutics Inc. published this content on February 20, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2025 at 12:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]